Edesa Biotech, Inc. (NASDAQ: EDSA) was established in 2015 and is headquartered in Markham, Canada, with 10 full-time employees. It is a clinical-stage biopharmaceutical company engaged in dermatology and gastrointestinal tract Development and research of indication treatment.
Edesa Biotech, Inc. (EDSA):
Edesa Biotech, Inc. is a clinical stage biopharmaceutical company founded by experts in the fields of dermatology and gastroenterology. The company is exploring new ways to treat these diseases, including alternatives to topical steroids. The original products may have serious side effects. The company’s new approach aims to inhibit the initiation of the inflammatory process by developing proprietary technologies, rather than treating inflammation after it has occurred.
Edesa Biotech’s main product candidate is EB01, a non-steroidal anti-inflammatory molecule, used to treat chronic allergic contact dermatitis (non-steroidal anti-inflammatory drug for chronic allergic contact dermatitis).
Edesa Biotech also intends to expand its product line to multiple indications, including acne or other inflammatory diseases. For example, EB02 is a preparation developed to treat hemorrhoids.
Edesa Biotech has also obtained licenses for other technologies and is in discussions to expand its portfolio of investigational drugs for the treatment of other serious skin and gastrointestinal diseases.